BridgeMD
Compares treatment options for Breast Cancer
Official title Two Versus One Week Breast Radiotherapy (RT)
ClinicalTrials.gov ID: NCT06960707
What this study is testing
- What it's testing
- This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a "concomitant boost").
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults, women only
You may be able to join if
- Women status post segmental mastectomy.
- If unilateral, pT1-2 breast cancer excised with negative margins.
- If bilateral, pT1-2 breast cancer excised with negative margins AND/OR pTis excised with negative margins.
- Clinically N0 (cN0 as determined by ultrasound/SOUND criteria) or pN0-1 or Nx or sentinel node negative.
- Ductal carcinoma in situ DCIS with negative margins (no DCIS on inked margins).
You likely can't join if
- Previous radiation therapy to the ipsilateral breast.
- \>90 days from last surgery, unless s/p adjuvant chemotherapy.
- \>60 days from last chemotherapy.
- Male breast cancer.
- Ongoing treatment for severe autoimmune disease.
See the full eligibility criteria
- Women status post segmental mastectomy.
- If unilateral, pT1-2 breast cancer excised with negative margins.
- If bilateral, pT1-2 breast cancer excised with negative margins AND/OR pTis excised with negative margins.
- Clinically N0 (cN0 as determined by ultrasound/SOUND criteria) or pN0-1 or Nx or sentinel node negative.
- Ductal carcinoma in situ DCIS with negative margins (no DCIS on inked margins).
- Women with previous contralateral treated breast cancer can be enrolled in the trial.
- Previous radiation therapy to the ipsilateral breast.
- \>90 days from last surgery, unless s/p adjuvant chemotherapy.
- \>60 days from last chemotherapy.
- Male breast cancer.
- Ongoing treatment for severe autoimmune disease.
The study team makes the final eligibility decision.
Where it's taking place
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New York, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.